Market Intelligence

The latest UK generic pricing information from WaveData shows multiple products doubling or even trebling their average prices in June.

Pregabalin topped our table of Biggest Risers in May, in another month of multiple treble-digit-percentage average price increases for the UK generics market.

With UK shortages and price rises making headlines in early 2024, April’s generic pricing data suggested an easing of pricing increases, according to the latest figures from WaveData.

Europe’s biosimilars market now has many years of progress under its belt. But how can this successful foundation be built upon to make the most of the opportunities on the horizon and achieve even greater access and uptake? In an exclusive interview, Generics Bulletin talks to Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil about the next steps.

Cigna’s Evernorth has announced plans to make a Humira biosimilar available for $0 out-of-pocket for Accredo patients from June, adding to momentum for adalimumab rivals from previous policy changes made by CVS in recent weeks. Meanwhile, AbbVie has offered the latest on how competition to its once top-selling brand is ramping up.

After getting off to a slow start last year, US biosimilar rivals to Humira are beginning to gain more traction. Sandoz is increasing its share on a weekly basis, Alvotech and Teva have struck a deal for their newly-approved interchangeable 100mg/ml biosimilar, and the latest market data shows biosimilars capturing twice as much of the market in Q1 as in Q4 2023.

 The US off-patent association published an analysis of IQVIA data, which highlights the role of rebate schemes that is slowing the adoption of Humira biosimilars that would save billions of dollars.

Price increases from multiple suppliers pushed vardenafil to the top of our Biggest Risers table for March 2024.

Following what Cardinal Health described as “a year of monumental developments in biosimilars,” the firm’s director of biosimilars, Dracey Poore, spoke to Generics Bulletin for an exclusive Q&A.

A raft of different generics saw their average UK trade price more than double in February 2024, according to the latest figures from market researcher WaveData.

Azithromycin topped our rundown of the steepest UK generic trade price rises in January 2024, based on figures from WaveData.

The current cost-saving benefits of biosimilars may soon be overturned by an unsustainable system that favors originator drugs, lower profits, and increased discounts, according to a new report.

As AbbVie reported fourth-quarter and full-year results for 2023, the firm set out its expectations for adalimumab biosimilar competition to Humira in the year ahead, particularly in the US.

A year to the day since the launch of the first US rival to Humira, adalimumab biosimilars are still struggling to gain a significant foothold in the market. Generics Bulletin looks at the reasons why.

As a number of major brands face generic and biosimilar competition, the loss-of-exclusivity impact across the leading 10 developed markets will approach $200bn over the next five years, according to a fresh medicines spending report running to 2028.

Formycon has reported positive uptake trends in the US for its Coherus-partnered ranibizumab biosimilar at the end of 2023, mirroring recent success in the UK with marketing ally Teva.